Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.



Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

WordPress Tables Plugin

Metro Mining (ASX:MMI) will expand production at the Bauxite Hills mine to 7 million tonnes per annum, thanks to a $45.5m loan from US investment manager Nebari Partners.

“The transaction minimises dilution and maximises value per share for shareholders compared to a dilutive equity raise, offering an NPV/share of ~A$0.0681 versus ~A$0.0412 if Metro had raised A$45M as equity,” MMI says.

The all-powerful FDA has approved Neuren Pharmaceuticals’ (ASX:NEU) DAYBUE, the first approved treatment for Rett syndrome.

Neuren will receive US$40 million on first commercial sale (April-May 2023), plus royalties on net sales, potential sales milestone payments and one third of the market value of the Rare Pediatric Disease Priority Review Voucher (PRV).



Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

WordPress Tables Plugin

Explorer Peako (ASX:PKO) will raise $1.5m at 1c per share (a 17% discount to the last closing price) for exploration at the Eastman PGE project in the Kimberley.